Information Provided By:
Fly News Breaks for September 14, 2015
CYNO
Sep 14, 2015 | 07:29 EDT
As noted earlier, Stifel upgraded Cynosure to Buy from Hold. The firm says that sales of the company's MonaLisa Touch product for vaginal atrophy are tracking towards $6M-$8M per quarter, versus the consensus outlook of $1M-$2M per quarter. The firm thinks that the company's base business appears to be weaker than initially thought, but it estimates that the company's overall revenue will still meet or exceed its estimates. Stifel adds that MonaLisa could be marketed overseas, while the company is developing a new flagship product. Target $44.
News For CYNO From the Last 2 Days
There are no results for your query CYNO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.